Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Core Insights - Zero Candida Technologies, Inc. is scaling production to 250 clinical-grade prototypes of its ZC-001 therapeutic device, which is a significant step in its regulatory roadmap [1] - The company plans to initiate a clinical study involving at least 100 women in Q4 2026 to evaluate the efficacy of the device, which has shown 99.999% fungal eradication in prior laboratory tests [1] - ZC-001 is an AI-enabled device designed for personalized at-home treatment of Vulvovaginal Candidiasis (VVC), aiming to improve outcomes for recurrent and drug-resistant infections [1] Company Overview - Zero Candida Technologies, Inc. is a publicly traded FemTech company focused on innovative solutions for women's health, particularly addressing the unmet needs related to VVC [1] - The company is developing a SMART device that combines AI and therapeutic blue light to treat VVC, which affects approximately 75% of women globally [1] - The VVC treatment market is projected to exceed US $2 billion by 2030, indicating significant growth potential for the company [1] Production and Development - The production of 250 clinical-grade prototypes is expected to be completed within 90 days, facilitating the transition from laboratory validation to human studies [1] - The device integrates precision blue light therapy, targeted drug delivery, and wireless diagnostics, which may also support future applications in other areas of women's health [1] - The company emphasizes its commitment to medical-grade excellence through adherence to ISO 13485-certified quality standards [1]